PILL.CN - Canntab Therapeutics Limited
| Previous Close | 0.3900 |
| Open | 0.4000 |
| Bid | 0.4000 x 0 |
| Ask | 0.4600 x 0 |
| Day's Range | 0.4000 - 0.4600 |
| 52 Week Range | 0.2700 - 0.9500 |
| Volume | 6,550 |
| Avg. Volume | 17,069 |
| Market Cap | 11.641M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar. 07, 2016 |
| 1y Target Est | N/A |
CNW GroupCanntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m
TORONTO, March 16, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the "Private Placement") by issuing 1,291,000 units ("Units") at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total gross proceeds of $3,725,500 under the Private Placement.
CNW GroupCanntab Announces Replacement of Advisor Warrants and Intention to Appoint Larry Latowsky as Director and Executive Chairman of the Board
TORONTO, March 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it intends to issue 500,000 common share purchase warrants (the "Replacement Warrants") to Larry Latowsky and that, subject to Health Canada approval, Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board. Each Replacement Warrant will be exercisable at a price of $0.60 per share until March 4, 2025. Issuance of the Replacement Warrants is subject to Mr. Latowsky's agreement to cancel an equivalent number of common share purchase warrants exercisable at a price of $1.00 per share.
- Newsfile
Canntab Announces Cancellation of Options and Issuance of Warrants
Toronto, Ontario--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that the Board of Directors passed a resolution to issue 1,300,000 warrants ("Warrants") to purchase common shares ("Common Shares") of the Company to employees, advisors and consultants of the Company. Each Warrant will entitle the holder to ...
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Receipt of its Cannabis Standard Processing and Sales for Medical Purposes Licence from Health Canada and Close of 1st Tranche of Private Placement - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has received its Cannabis Standard Processing and Sales for Medical Purposes Licence from Health Canada. This follows the recent grant by Health Canada of a Cannabis Research Licence. These new licences will enable the company to submit Notice of New Cannabis ...
- CNW Group
Canntab Receives Health Canada Licence and Closes $3.08M Offering
TORONTO , March 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that on Friday, February 28 th, 2020 it successfully received its Cannabis Standard Processing & Sales for Medical Purposes Licences from Health Canada, and that it has closed the first tranche (the "First Tranche") of its non-brokered private placement offering (the "Private Placement") for total gross proceeds of $3,080,000 .
- Newsfile
InvestmentPitch Media Video Discusses Canntab's Receipt of Cannabis Research Licence from Health Canada - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2020) - Canntab Therapeutics (CSE: PILL) (OTCQX: CTABF) (FSE: TBF1), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, has been granted a Cannabis Research Licence by Health Canada. The research licence will allow Canntab to receive oil and continue research and development of the company's growing line of next generation medical cannabis solutions at the company's Markham Ontario Facility.For ...
CNW GroupCanntab Awarded Health Canada Cannabis Research Licence
TORONTO , Feb. 24, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that Health Canada has granted the Company a Cannabis Research Licence for the purpose of continuing research and development of the Company's growing line of next generation medical cannabis solutions at the Company's Markham Ontario Facility.
CNW GroupCanntab Announces Non-Brokered Private Placement
TORONTO, Feb. 6, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it is launching a private placement (the "Private Placement") of up to $2.5 million of units ("Units"), subject to the Company's over-allotment option to increase the size of the Private Placement by up to an additional $1.5 million, at a price of $0.50 per Unit, with each Unit consisting of one common share and one full warrant to acquire an additional common share at a price of $0.75 per share for a period of two years. Canntab expects to close the Private Placement on or before February 20th, 2020. Canntab's expansion through its wholly owned US subsidiary Canntab USA, Inc. into the State of Florida jointly with Exactus Inc. for the manufacture of a CBD hard pill (non-THC) in formulations for sale and distribution across the United States.
CNW GroupCanntab Submits Site Evidence Package to Health Canada to Obtain LP Status
The final step to obtain a licence to process Canntab's cannabis hard pill formulation, at its fully built out Markham, Ontario facility. Retains Larry Latowsky, former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab's commercialization efforts. TORONTO, Dec. 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company's Site Evidence Package to Health Canada for approval of their Licence Producer Status (Processing-Standard, Federal Sales-Medical).
